Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Receivables (2020 - 2022)

Historic Receivables for Tango Therapeutics (TNGX) over the last 3 years, with Q4 2022 value amounting to $2.0 million.

  • Tango Therapeutics' Receivables changed 0.0% to $2.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $2.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $2.0 million for FY2022, which is 0.0% changed from last year.
  • As of Q4 2022, Tango Therapeutics' Receivables stood at $2.0 million, which was down 0.0% from $2.0 million recorded in Q3 2022.
  • Tango Therapeutics' Receivables' 5-year high stood at $8.0 million during Q3 2021, with a 5-year trough of $2.0 million in Q4 2020.
  • In the last 3 years, Tango Therapeutics' Receivables had a median value of $2.0 million in 2020 and averaged $2.9 million.
  • In the last 5 years, Tango Therapeutics' Receivables changed by 0.0% in 2021 and then plummeted by 7500.0% in 2022.
  • Quarter analysis of 3 years shows Tango Therapeutics' Receivables stood at $2.0 million in 2020, then changed by 0.0% to $2.0 million in 2021, then changed by 0.0% to $2.0 million in 2022.
  • Its last three reported values are $2.0 million in Q4 2022, $2.0 million for Q3 2022, and $2.0 million during Q2 2022.